erlotinib hydrochloride has been researched along with isobutyrylshikonin in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (isobutyrylshikonin) | Trials (isobutyrylshikonin) | Recent Studies (post-2010) (isobutyrylshikonin) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 5 | 0 | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q | 1 |
1 other study(ies) available for erlotinib hydrochloride and isobutyrylshikonin
| Article | Year |
|---|---|
Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Naphthoquinones; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |